Dr. Michel J. Tremblay is a regular researcher in the field of infectious and immune diseases at the CHU Research Center of Québec-Laval University. He is also a Professor in the Department of Microbiology-Infectiology and Immunology of the School of Medicine at Laval University, and holds the Canada Research Chair in Human Immuno-Retrovirology.

He has been Vice-Dean, Research and Graduate Studies at the Faculty of Medicine, and is currently Assistant Vice-President, Research, Creation and Innovation at Laval University. Dr. Tremblay has published over 200 articles in peer-reviewed scientific journals, and to date has received nearly $ 15 million in funding as a principal investigator and just under $ 40 million in funding as co-researcher for his research projects. Dr. Tremblay has received several awards and distinctions, including the André Dupont Award from the Clinical Research Club of Quebec and the Léo-Pariseau Award from ACFAS. Dr. Tremblay is a member of the Canadian Research Consortium on HIV Healing (CanCURE) which is funded by the Canadian Institutes of Health Research (CIHR).

His research aims to deepen our knowledge of the pathogenesis of human immunodeficiency virus (HIV) infection, the etiologic agent of Acquired Immunodeficiency Syndrome (AIDS). His research focuses on several facets of HIV infection, such as the complex interactions that occur between HIV and certain target cells of the virus (e.g., macrophages, CD4 T cells, astrocytes, etc.) and large-scale analysis of gene expression patterns following viral infection, using DNA microarrays and RNA sequencing in combination with powerful bioinformatic tools.

CHUL
2705, boulevard Laurier
R-2701.4
Québec, Québec
Canada G1V 4G2
210 entries « 22 of 21 »
210 entries « 22 of 21 »
Signaler des ajouts ou des modifications

Active projects

  • Canadian HIV Cure Enterprise 2.0: Targeting the interplay between myeloid cells and C04+ T-cells for HIV cure, from 2019-04-01 to 2025-03-31
  • Microglia as a viral reservoir for HIV-1 in the human brain and its role in neuroinflammation, from 2021-04-01 to 2026-03-31

Recently finished projects

  • Contribution - consortium Érudit, from 2022-01-01 to 2024-04-30
  • Manufacturing of antigens and adjuvants for development of vaccines (MAAV), from 2021-07-01 to 2024-03-31
Data provided by the Université Laval research projects registery